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Fetal growth in gestational diabetes mellitus (GDM) is directly linked to maternal glycaemic
control; however, this relationship may be altered by oral anti-hyperglycaemic agents.
Unlike insulin, such drugs cross the placenta and may thus have independent effects on
fetal or placental tissues. We investigated the association between GDM treatment and
fetal, neonatal, and childhood growth.
Methods and findings
PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and Cochrane data-
bases were systematically searched (inception to 12 February 2020). Outcomes of GDM-
affected pregnancies randomised to treatment with metformin, glyburide, or insulin were
included. Studies including preexisting diabetes or nondiabetic women were excluded. Two
reviewers independently assessed eligibility and risk of bias, with conflicts resolved by a
third reviewer. Maternal outcome measures were glycaemic control, weight gain, and treat-
ment failure. Offspring anthropometric parameters included fetal, neonatal, and childhood
weight and body composition data. Thirty-three studies (n = 4,944), from geographical loca-
tions including Europe, North Africa, the Middle East, Asia, Australia/New Zealand, and the
United States/Latin America, met eligibility criteria. Twenty-two studies (n = 2,801) rando-
mised women to metformin versus insulin, 8 studies (n = 1,722) to glyburide versus insulin,
and 3 studies (n = 421) to metformin versus glyburide. Eleven studies (n = 2,204) reported
maternal outcomes. No differences in fasting blood glucose (FBS), random blood glucose
(RBS), or glycated haemoglobin (HbA1c) were reported. No studies reported fetal growth
parameters. Thirty-three studies (n = 4,733) reported birth weight. Glyburide-exposed
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neonates were heavier at birth (58.20 g, 95% confidence interval [CI] 10.10–106.31, p =
0.02) with increased risk of macrosomia (odds ratio [OR] 1.38, 95% CI 1.01–1.89, p = 0.04)
versus neonates of insulin-treated mothers. Metformin-exposed neonates were born lighter
(−73.92 g, 95% CI −114.79 to −33.06 g, p < 0.001) with reduced risk of macrosomia (OR
0.60, 95% CI 0.45–0.79, p < 0.001) than insulin-exposed neonates. Metformin-exposed
neonates were born lighter (−191.73 g, 95% CI −288.01 to −94.74, p < 0.001) with a nonsig-
nificant reduction in macrosomia risk (OR 0.32, 95% CI 0.08–1.19, I2 = 0%, p = 0.09) versus
glyburide-exposed neonates. Glyburide-exposed neonates had a nonsignificant increase in
total fat mass (103.2 g, 95% CI −3.91 to 210.31, p = 0.06) and increased abdominal (0.90
cm, 95% CI 0.03–1.77, p = 0.04) and chest circumferences (0.80 cm, 95% CI 0.07–1.53, p =
0.03) versus insulin-exposed neonates. Metformin-exposed neonates had decreased pond-
eral index (−0.13 kg/m3, 95% CI −0.26 to −0.00, p = 0.04) and reduced head (−0.21, 95% CI
−0.39 to −0.03, p = 0.03) and chest circumferences (−0.34 cm, 95% CI −0.62 to −0.05, p =
0.02) versus the insulin-treated group. Metformin-exposed neonates had decreased pond-
eral index (−0.09 kg/m3, 95% CI −0.17 to −0.01, p = 0.03) versus glyburide-exposed neo-
nates. Study limitations include heterogeneity in dosing, heterogeneity in GDM diagnostic
criteria, and few studies reporting longitudinal growth outcomes.
Conclusions
Maternal randomisation to glyburide resulted in heavier neonates with a propensity to
increased adiposity versus insulin- or metformin-exposed groups. Metformin-exposed neo-
nates were lighter with reduced lean mass versus insulin- or glyburide-exposed groups,
independent of maternal glycaemic control. Oral anti-hyperglycaemics cross the placenta,
so effects on fetal anthropometry could result from direct actions on the fetus and/or pla-
centa. We highlight a need for further studies examining the effects of intrauterine exposure
to antidiabetic agents on longitudinal growth, and the importance of monitoring fetal growth
and maternal glycaemic control when treating GDM. This review protocol was registered
with PROSPERO (CRD42019134664/CRD42018117503).
Author summary
Why was this study done?
• Gestational diabetes mellitus (GDM) is an increasing healthcare concern that has signif-
icant short- and long-term health implications for mother and baby.
• Optimising clinical treatment of GDM is an important priority. Several current treat-
ment options exist, including insulin or oral therapies, such as metformin or glyburide.
• We aimed to investigate the associations between different GDM treatments and the
growth of the baby in the womb, at birth, during childhood, and in later life.
PLOS MEDICINE GDM treatment and maternal and postnatal outcomes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003126 May 22, 2020 2 / 23
supported by a grant from the Addenbrooke’s
Charitable Trust (ACT) (https://www.
act4addenbrookes.org.uk/) and by an Isaac
Newton Trust/Wellcome Trust ISSF/ University of
Cambridge Joint Research Grant (https://www.
newtontrust.cam.ac.uk/). The funders had no role
in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: ABC, ATP-binding cassette protein;
ACOG, American College of Obstetrians and
Gynecologists; ADA, American Diabetes
Association; ADIPS, Australasian Diabetes in
Pregnancy Society; AMPK, 50 AMP-activated
protein kinase; BHM, Brazilian Health Ministry; CC,
Carpenter-Coustan; CDA, Canadian Diabetes
Association; CI, confidence interval; FBS, fasting
blood glucose; FDA, Food and Drug Administration;
FNC, Finnish National Criteria; GDM, gestational
diabetes mellitus; HbA1c, glycated haemoglobin;
IADPSG, International Association of Diabetes and
Pregnancy; ITT, intention-to-treat; LGA, large for
gestational age; LOO, leave-one-out; mTOR,
mammalian target of rapamycin; N/A, Non-
Applicable; NDDG, National Diabetes Data Group;
NICE, National Institute for Clinical Excellence; OR,
odds ratio; PRISMA, Preferred Reporting Items for
Systematic Reviews and Meta-Analyses; RACGP,
Royal Australian College of General Practitioners;
RBS, random blood glucose; SMFM, Society of
Maternal-Fetal Medicine; WHO, World Health
Organization.
What did the researchers do and find?
• We performed a systematic review of 33 studies that included 4,944 mothers who were
randomised to insulin, metformin, or glyburide for treatment of GDM. We included all
studies that reported the weight and growth of their babies in the womb, at birth, or
later in childhood.
• Babies exposed to glyburide are significantly heavier at birth compared to those whose
mothers were randomised to insulin or metformin. Conversely, metformin-exposed
babies are significantly lighter at birth than those whose mothers were randomised to
insulin or glyburide.
• There may also be differences in body composition at birth. Babies exposed to glyburide
tend to be born larger with increased fat mass, and babies exposed to metformin were
born smaller and were thinner, compared to those treated with insulin.
What do these findings mean?
• There are significant differences in body mass between babies whose mothers were ran-
domised to glyburide, metformin, and insulin to treat GDM. Our results highlight the
importance of considering the effects of treatment on both mother and baby when man-
aging GDM.
• There is a need for better understanding of exactly how oral treatments for GDM impact
on growth of babies in the womb and in later life, particularly whether there are implica-
tions for long-term health.
Introduction
Gestational diabetes mellitus (GDM) is an increasing healthcare concern, affecting 3% to 25%
of pregnancies worldwide [1]. It was estimated in 2017 that approximately one in seven babies
globally was born to a mother with GDM [2]. GDM has significant short- and long-term
health implications for mother and baby, particularly if untreated or undertreated, making
optimal clinical management of GDM an important priority. Poorly managed or untreated
GDM leads to accelerated fetal growth [3] and therefore increases the risk of macrosomic and
large-for-gestational-age neonates [4,5]. Pregnancies affected by GDM that are not adequately
managed are consequently at risk of adverse neonatal outcomes, both immediately; e.g., shoul-
der dystocia, birth trauma, including birth hypoxic injuries, and neonatal hypoglycaemia [6–
8], and in the longer term; e.g., metabolic dysregulation in later childhood [9,10]. Hence, it is
essential to implement effective clinical interventions to maintain maternal glycaemic control,
with the dual aim of maintaining fetal growth within normal parameters, thereby protecting
both mother and baby from adverse outcomes.
In around two thirds of GDM-affected pregnancies, maternal euglycaemia can be main-
tained by implementing strategies for altering diet and lifestyle [11]. However, at least one
third of affected women will require pharmacological therapies to achieve their treatment
goals [12]. Three commonly used pharmacological options are available: insulin, metformin,
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and glyburide (also known as glibenclamide). However, there is little international consensus
on optimal management strategies, in particular, which pharmacological agent(s) should be
offered as first-line therapies. The endogenous hormone insulin [13] is recommended as the
first-line treatment for GDM by several organisations, including the American Diabetes Asso-
ciation (ADA) [14], the American College of Obstetrians and Gynecologists (ACOG) [15] and
the Canadian Diabetes Association (CDA) [16]. Metformin (N,N-dimethylbiguanide), a
biguanide oral insulin sensitiser and glucose-lowering drug, is recommended by the Society of
Maternal-Fetal Medicine (SMFM) as a first-line treatment for GDM [17]. The United King-
dom’s regulatory body, the National Institute for Clinical Excellence (NICE) recommends
metformin for use in GDM as an adjunct or alternative to insulin in GDM management [18].
New Zealand’s regulatory body also recommends metformin for the treatment of GDM [19].
Glyburide (5-chloro-N(2-{4-[N-(N-cyclohexylcarbomoyl)sulfamoyl]phenyl}ethyl)-2-methox-
ybenzamide) belongs to the sulphonylurea class of antidiabetic agents, which stimulates insulin
secretion from pancreatic beta cells, thereby reducing hyperglycaemia. Both the ADA [14] and
the ACOG [15] consider its use acceptable in GDM. In the UK, NICE guidelines suggest con-
sidering glyburide only for women with gestational diabetes who do not respond to or cannot
tolerate metformin but decline insulin [18]. However, the Food and Drug Administration
(FDA) classifies glyburide as a Category C class drug (not approved in GDM), and in Australia,
the Royal Australian College of General Practitioners (RACGP) [20] suggests it should be used
with caution. Given the range of international opinion, there is a need to fully understand the
risks and benefits of each option, not only for the mother but also for the developing fetus, in
the short and long term.
The dual goals of clinical GDM management (achieving maternal euglycaemia and main-
taining normal fetal growth trajectory) are often assumed to be directly linked. This is the case
if GDM is controlled with dietary modification and also if using insulin, which does not cross
the placenta [21], although it is possible that insulin could have additional effects at the
materno-fetal interface. However, the commonly used oral anti-hyperglycaemic agents met-
formin and glyburide both cross the placenta to varying degrees. Recent work shows umbilical
cord serum concentrations of metformin at the time of delivery are comparable to or exceed
maternal concentrations [22–24], and it is present at clinically relevant concentrations in fetal
and placental tissues (50%–100% of maternal concentrations) [22,23]. Studies have also shown
placental transfer of glyburide, with concentrations of glyburide in umbilical cord plasma
approximately 70% of maternal levels [25–27]. These findings suggest that there is potential
for both metformin and glyburide to exert effects on the developing fetus and on the placenta
via direct or indirect pathways, independent of maternal glycaemic control.
Hence, while fetal growth can be assumed to be directly indexed to maternal glucose levels
in GDM treated with diet or insulin, there is the possibility of the uncoupling of maternal gly-
caemic control and fetal growth as a result of treatment with metformin or glyburide. The aim
of this study was therefore to provide a systematic, unbiased, and comprehensive overview of
the comparative impacts of various pharmacological treatments for GDM on fetal growth,
neonatal anthropometry, and childhood growth outcomes, including considering the effects of
maternal glycaemic control.
Materials and methods
This systematic review and meta-analysis was conducted in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [28]. The
PRISMA checklist is detailed in S1 PRISMA Checklist. The systematic review protocol was
registered in PROSPERO CRD42019134664 (S1 Text). Metformin versus insulin data were
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derived from PROSPERO protocol CRD42018117503 [29]. Ethical approval was not required
for this meta-analysis.
Literature searches, search strategies, and eligibility criteria
Systematic literature searches using prespecified terms (S2 Text) were performed on PubMed
(June 1997 to 12 February 2020), Ovid EMBASE (1974 to 12 February 2020), Ovid Medline
(1946 to 12 February 2020), Cochrane Library (database inception to 12 February 2020), Clini-
caltrials.gov (database inception to 12 February 2020), and Web of Science (1900 to 12 Febru-
ary 2020). Details for the database search strategies for metformin versus insulin comparisons
can be found in [29]. No language or location restrictions were applied. Studies that rando-
mised women with GDM to glyburide versus insulin therapy, metformin versus insulin ther-
apy, and metformin versus glyburide therapy were included. Studies were excluded if they
investigated other oral anti-glycaemic agents (such as myo-inositol), or if interventions were
given prior to pregnancy. GDM was screened for and diagnosed according to local criteria in
each study, and we did not apply exclusions with respect to this. Studies were excluded if they
included participants with multiple pregnancies or preexisting diabetes, or if they randomised
fewer than 50 women in total. Studies were also excluded if they were not analysed on an
intention-to-treat (ITT) basis. Studies were excluded if trial participants were omitted from
the study on the basis of fetal weight and/or birth weight. Data reported only in meeting
abstracts would have been included if the abstract contained sufficient information for assess-
ment, but none met this criterion. Where insufficient information for assessment was avail-
able, authors were contacted for further information. Three studies provided insufficient
information for assessment; however, none of these authors responded to contact, and there-
fore these studies were not included in the analysis.
Study selection and data extraction
Two reviewers (JLA and CEA) independently assessed each study using predetermined inclu-
sion/exclusion criteria (detailed in S1 Table). A third reviewer (SEO) was available to resolve
cases for which eligibility was unclear. An initial screen of titles and abstracts was performed,
followed by a detailed full paper screen (Fig 1).
Data extraction from eligible studies was conducted independently using a standardised
proforma by two authors (JLA and CEA). Fetal and neonatal outcome measures were as fol-
lows: fetal growth parameters (head circumference, abdominal circumference, femur length,
biparietal diameter, estimated fetal weight calculated by any formula), birth weight (g or kg),
large for gestational age (LGA: birth weight >90th percentile for gestational age), macrosomia
(birth weight >4 kg), neonatal ponderal index (kg/m3), neonatal abdominal, head, chest, and
waist circumferences (cm), neonatal skinfold thicknesses (mm), and neonatal fat masses (total
and abdominal; g). We also collected data on maternal outcomes that reflected the adequacy of
GDM control: fasting blood glucose (FBS; mg/dL), random blood glucose (RBS, average
2-hour postprandial glucose measurements; mg/dL), glycated haemoglobin (HbA1c; %), treat-
ment failure rates (defined as per the criteria from each original study), and gestational weight
gain (kg). FBS and RBS were measured in the last two weeks of pregnancy by two studies
[30,31], and one study did not specify when these measurements were taken [32]. All studies
reported that HbA1c values were taken just before delivery. Gestational weight gain was mea-
sured throughout pregnancy in most studies [33–42]. Other studies measured this outcome
from treatment start until the end of pregnancy [31,34,41–45].
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Quality assessment of included studies (risk of bias in individual studies)
Each study was independently assessed by two authors (JLA and CEA) for quality and validity
using the Cochrane Collaboration tool for assessing risk of bias. Seven risk of bias domains
were assessed for each study and each domain was given a rating of low risk, unknown risk, or
high risk of bias (S2 Table). All risk of bias analysis was conducted at the study level.
Fig 1. PRISMA flow diagram (metformin versus insulin, glyburide versus insulin, glyburide versus metformin). PRISMA, Preferred Reporting
Items for Systematic Reviews and Meta-Analyses.
https://doi.org/10.1371/journal.pmed.1003126.g001
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The principle summary measures utilised in this systematic review were unadjusted odds
ratios (ORs) (for dichotomous data) or differences in means (for continuous data). Meta-anal-
ysis was performed using Review Manager (RevMan) Version 5.3, Copenhagen: The Nordic
Cochrane Centre, the Cochrane Collaboration, 2014) and the ‘metafor’ package in R version
3.5.1 [46]. Funnel plots were constructed to assess publication bias. Meta-analyses with 5 or
more studies included were also subjected to Egger’s test. Heterogeneity between studies was
assessed using the I-squared statistic, and any outcomes showing significant inter-study het-
erogeneity were analysed using a random-effects model. Sensitivity analyses were performed
using ‘leave-one-out’ (LOO) sensitivity testing for individual studies, ‘leave-one-criteria-out’
sensitivity testing for studies grouped according to GDM criteria, and ‘leave-one-continent-
out’ sensitivity analysis for studies grouped according to geographical location [29]. Where p-
values are reported, an alpha level<0.05 was considered statistically significant.
Results
For the comparisons of drug treatments for gestational diabetes, electronic searching of the
specified databases yielded a total of 3,373 studies. After removal of duplicates and title/
abstract screening, 157 trials were screened for full-text assessment, applying the full set of eli-
gibility criteria. After full-text evaluation, a total of 40 studies remained eligible for inclusion.
Seven studies were removed due to not being analysed on an ITT basis, leaving 33 studies for
meta-analysis (Fig 1). This represented a total 4,944 pregnancies (Table 1). For all compari-
sons, the studies varied with respect to quality and design (S3 Table). Measured outcomes var-
ied between studies and comparisons, with birth weight the single most commonly reported
outcome (Table 1).
The doses of glyburide (1.25 mg to 20 mg daily) and metformin (500 mg to 3,000 mg daily)
demonstrated considerable heterogeneity, both within and between studies. Heterogeneity
also existed between studies in criteria used to diagnose GDM, with a total of 9 different
diagnostic criteria used. These were the ADA, Australasian Diabetes in Pregnancy Society
(ADIPS), Brazilian Health Ministry (BHM), Carpenter-Coustan (CC), Finnish National Crite-
ria (FNC), International Association of Diabetes and Pregnancy (IADPSG), National Diabetes
Data Group (NDDG), World Health Organization (WHO), and unspecified GDM criteria.
LOO sensitivity analysis demonstrated that use of different thresholds for GDM diagnosis did
not have a significant impact on the meta-analyses for birth weight (S1 Fig). In general, there
was also a range of geographical settings, including Europe [33,34,47,48–50] (six studies;
n = 1,528), Australia/New Zealand [43,51,52] (three studies; n = 1,259), Latin America [36–
39,44] (five studies; n = 483), North Africa/Middle East [30–32,40,41,45] (six studies; n = 637),
the US [35,53–55] (four studies; n = 698), and South East Asia [42,56–59] (five studies;
n = 1,113). More studies from North Africa/Middle East [30,31,40,41,45] (five studies; n = 542)
and Europe [33,34,47–49] (five studies; n = 719) compared metformin with insulin. More
studies from the US/Latin America [35–39,53,54,55] (eight studies; n = 1,900) compared
Table 1. Study and participant numbers.
Study type Glyburide versus insulin Metformin versus insulin Metformin versus glyburide
All included studies 8 studies (n = 1,722) 22 studies (n = 2,801) 3 studies (n = 421)
Fetal growth 0 studies (n = 0) 0 studies (n = 0) 0 studies (n = 0)
Birth weight 7 studies (n = 1,651) 11 studies (n = 1,820) 3 studies (n = 421)
Neonatal anthropometry 8 studies (n = 1,722) 12 studies (n = 2,590) 3 studies (n = 421)
Infant/child growth 0 studies (n = 0) Up to 3 studies (n = 986) 0 studies (n = 0)
https://doi.org/10.1371/journal.pmed.1003126.t001
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glyburide with either insulin or metformin. Leave-one-continent-out sensitivity analysis
showed that the difference in birth weight between glyburide versus insulin groups became
nonsignificant after leaving out studies from the US/Latin America. Similarly, the difference in
birth weight between metformin versus insulin groups became nonsignificant after leaving out
studies from North Africa/Middle East [30,31,40,41,45] (S2 Fig). Metformin versus glyburide
studies only originated from the US/Latin America, and therefore leave-one-continent out
analysis was not conducted.
Overall, the risk of bias was moderate to low in the majority of included studies (S2 Table).
We assessed the likelihood of single studies significantly influencing the overall results using
leave-one-study out sensitivity analysis. Regarding maternal outcomes, of 13 meta-analyses
performed, three were not robust to leave-one-study-out testing (gestational weight gain com-
paring metformin with insulin; gestational weight gain comparing metformin with glyburide;
FBS comparing metformin with insulin) (S3 Fig). Of the nine meta-analyses examining neona-
tal growth outcomes, three were not robust to leave-one-study-out testing (birth weight com-
paring glyburide with insulin; LGA comparing metformin with glyburide; macrosomia
comparing metformin with insulin). Funnel plots for all outcomes were assessed visually for
asymmetry (S4 Fig). Egger’s testing demonstrated no evidence of publication bias in any out-
comes or comparisons, with the exception of birth weight for studies comparing glyburide
with insulin and for FBS when comparing metformin with insulin (S4 Table).
Maternal demographics and outcomes
Table 2 reports the demographic data of the participants of the included studies in this meta-
analysis. Maternal age at randomisation was similar between studies, with an average age of 30
years. BMI ranged between 24 and 35 kg/m2, with most studies including women with an aver-
age BMI of approximately 30 kg/m2. The majority of studies randomised women between 20
and 36 weeks of gestation [31,32,34,42,43,44,48,49,50,51,52,53,54,58], although others [36–
39,55] randomised women between 11 and 33 weeks of gestation. Gestational age at study
entry was consistent across studies, at around 30 weeks of gestation.
Measures of maternal glycaemic control at the end of pregnancy were not significantly dif-
ferent for any of the treatment comparisons when assessed by FBS, RBS, or HbA1c (S5 Fig). In
all included studies, supplementation with insulin was available to achieve glycaemic control
within target ranges. The treatment failure rate (the number of women who needed supple-
mentation with insulin to maintain glycaemic control) in the glyburide versus insulin compar-
isons ranged from 0% to 21%, with a weighted average failure rate of 12.9%. In metformin
versus insulin comparisons, treatment failure rates ranged from 14% to 46%, with a weighted
average failure rate of 33.2%. In the studies directly comparing metformin versus glyburide,
women were more likely to require supplementary insulin when treated with metformin than
with glyburide (OR 0.62, 95% confidence interval [CI] 0.40–0.97, I2 = 45%, p = 0.04).
Three studies [35,36,53], including 523 women, recorded total gestational weight gain in
glyburide compared to insulin-treated women. No difference in total gestational weight gain
was observed between glyburide versus insulin-treated women (−0.68 kg; 95% CI −1.69 kg to
0.34 kg; I2 = 0%, p = 0.19) (Fig 2A). Five studies [33,34,40,42,56], including 689 women, mea-
sured gestational weight gain in women treated with metformin versus insulin. Metformin-
treated mothers gained less weight over the total pregnancy compared to those treated with
insulin (−1.31 kg; 95% CI −2.34 kg to −0.27 kg; I2 = 80%, p = 0.01) (Fig 2B). Two studies [49,
50], including 272 women, showed that those treated with metformin also gained significantly
less weight over the whole pregnancy compared to those treated with glyburide (−2.20 kg; 95%
CI −3.88 kg to −0.56 kg; I2 = 0%, p = 0.009) (Fig 2C). Six studies [31,34,43,40,41,44], including
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1,295 women, reported posttreatment weight gain in metformin- versus insulin-treated
women. This was very similar to the magnitude of difference in total gestational weight gain
(−1.31kg), demonstrating that the difference in weight gain between these groups was likely
due primarily to the allocated treatment (−1.15 kg; 95% CI −1.87 kg to −0.42 kg, I2 = 96%,
p = 0.002). No studies comparing glyburide to either insulin or metformin reported this out-
come measure.
With respect to maternal outcomes, several analyses failed the LOO sensitivity analysis (ges-
tational weight gain comparing metformin with insulin, gestational weight gain comparing
Table 2. Demographic information for women included in the meta-analysis.
First author Country Gestational age (weeks) at
randomisation
Maternal age (years) at
randomisation
BMI (kg/m2) at randomisation Gestational age at entry
(weeks)
Arshad (2017) Egypt 12–24 M: 29.8 ± 3.4; I: 31.6 ± 4.3 Not recorded Not recorded
Ashoush (2016) Pakistan 22–36 M: 31.6 ± 2.8; I: 32.1 ± 3.2 M: 31.3 ± 1.3; I: 31.4 ± 1.5 M: 29.8 ± 1.4; I: 29.7 ± 1.9
Barrett (2013) Australia 22–33 M: 33.3 (32.6–34); I: 32.9 (32.2–
33.5)
M: 34.5 (33.5–35.5); I: 33.8
(32.8–34.8)
Not recorded
Battin (2015) Australia 22–33 Not recorded Not recorded Not recorded
Bertini (2005) Brazil 11–33 G: 31.2 ± 4.5; I: 28.7 ± 6.0 G: 27.5 ± 5.8; I: 27. ± 7.2 Not recorded
Borg (2016) Egypt 22–36 M: 25 ± 4.6; I: 30 ± 4.0 M: 22.5 ± 4.9; I: 23.5 ± 3.7 Not recorded
Hassan (2012) Pakistan 20–36 M: 30.3 ± 3.0; I: 30.9 ± 3.6 M: 29.2 ± 1.9; I: 28.7 ± 2.7 M: 29.5 ± 1.3; I: 29.2 ± 1.5
Ijas (2011) Finland 12–34 M: 32.3 ± 5.6; I: 31.7 ± 5.6 M: 31.5 ± 6.5; I: 30.8 ± 5.4 Not recorded
Ijas (2015) Finland 12–34 M: 32.1 ± 5.1; I: 31.9 ± 6.2 M: 31 ± 6.2; I: 30.6 ± 5.4 M: 30 ± 4.5; I: 30.4 ± 4.1
Khan (2017) Pakistan Not recorded M: 24.9 ± 2.6; I: 28 ± 2.5 M: 22 ± 3; I: 23.8 ± 2.8 Not recorded
Lain (2009) US 24–33 G: 32.2 ± 5.0; I: 31.2 ± 5.9 G: 33.4 ± 12.9; I: 30.9 ± 5.7 Not recorded
Langer (2000) US 11–33 G: 29.0 ± 7.0; I: 30.0 ±6.0 Not recorded G: 24.0 ± 7.0; I: 25.0 ± 7.0
Mirzamoradi (2013) Iran 24–36 G: 29.5 ± 4.1; I: 31.2 ± 5.0 Not recorded Not recorded
Moore (2007) Mexico 20–34 Not recorded Not recorded Not recorded
Moore (2010) Mexico 11–33 M: 31 ± 7.1; G: 29.6 ± 7.8 M: 32.8 ± 5.8; G: 32.7 ± 7.0 M: 27.3 ± 7; G: 29.1 ± 5
Mukhopadhyay
(2012)
India 20–28 G: 26.3 ± 4.6; I: 26.0 ± 4.3 G: 23.7 ± 2.7; I: 23.0 ± 2.9 G: 28.3 ± 2.2; I: 27.4 ± 2.7
Niromanesh (2012) Iran 20–34 M: 30.7 ± 5.5; I: 31.8 ± 5.1 M: 28.1 ± 4.0; I: 27.1 ± 2.1 M: 28.7 ± 3.7; I: 28.6 ± 3.6
Rowan (2008) Australia 22–33 M: 33.5 ± 5.4; I: 33.0 ± 5.1 M: 35.1 ± 8.3; I: 34.6 ± 7.2 M: 30.2 ± 3.3; I: 30.1 ± 3.2
Rowan (2011) Australia 22–33 M: 39.4 ± 5.4; I: 38.9 ± 5.0 M: 33.4 ± 12; I: 31.6 ± 10.0 M: 30.4 ± 3.3; I: 30.0 ± 3.3
Rowan (2018) Australia 22–33 Not recorded Not recorded Not recorded
Saleh (2016) Egypt 26–34 M: 31.0 ± 3.4; I: 29.8 ± 2.2 M: 30.5 ± 3.1; I: 31.6 ± 3.1 M: 27.3 ± 3.5; I: 29.3 ± 3.1
Senat(2018) France 24–34 G: 32.5 ± 5.1; I: 32.6 ± 5.3 G: 30.7 ± 5.1; I: 31.1 ± 5.4 Not recorded
Silva (2007) Brazil 11–33 G: 31.6 ± 4.2; I: 29.9 ± 6.0 Not recorded Not recorded
Silva (2010) Brazil 11–33 M: 33.6 ± 5.8; G: 31.5 ± 5.4 Not recorded M: 26.8 ± 6; G: 25.6 ± 6.4
Silva (2012) Brazil 11–33 M: 31.3 ± 5.4; G: 32.6 ± 5.6 M: 28.7 ± 5.4; G: 28.6 ± 5.9 M: 25.4 ± 7; G: 26.9 ± 6.4
Somani (2016) India 24–34 M: 25.6 ± 4.7; I: 26.3 ± 3.8 Not recorded M: 27.8 ± 2.5; I: 28.3 ± 2.6
Spaulonci (2013) Brazil 24–28 M: 31.9 ± 6.0; I: 32.8 ± 4.7 M: 32.0 ± 4.8; I: 34.1 ± 5.7 M: 32.2 ±3.7; I: 32.0 ± 3.5
Tempe (2013) India 22–34 Not recorded Not recorded Not recorded
Tertti (2013) Finland 22–34 M: 31.5 ± 5.0; I: 32.1 ± 5.4 M: 29.4 ± 5.9; I: 28.9 ± 4.7 M: 30.3 ± 2; I: 30.4 ± 2
Tertti (2014) Finland 22–34 Not recorded Not recorded Not recorded
Tertti (2015) Finland 22–34 Not recorded M: 32.3 ± 5.2; I: 31.7 ± 5.0 Not recorded
Tertti (2016) Finland 22–34 Not recorded Not recorded Not recorded
Wouldes (2016) Australia 22–33 Not recorded Not recorded Not recorded
All outcomes signified with plus-minus sign ‘±’ are SD; outcomes signified with parentheses ‘()’ are 95% CI.
Abbreviations: CI, confidence interval; G, glyburide; I, insulin; M, metformin
https://doi.org/10.1371/journal.pmed.1003126.t002
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metformin with glyburide, and FBS comparing metformin with insulin), and these analyses
should therefore be interpreted with caution.
Fetal and neonatal outcomes
No eligible studies in any of the treatment comparison groups (glyburide versus insulin, met-
formin versus insulin, or metformin versus glyburide) reported any fetal growth data. In seven
studies including 1,651 participants [32,35,36,37,50,53,58], neonates exposed to glyburide
were significantly heavier at birth (58.20 g; 95% CI 10.10 g to 106.31g; I2 = 43%, p = 0.02) com-
pared to those born to mothers treated with insulin (Fig 3A). In 11 studies including 1,823
women [30,31,33,34,40–44,54,56], metformin-exposed neonates were significantly lighter at
birth compared to insulin-exposed neonates, with average birth weights 73.92 g lighter (95%
CI −114.79 g to −33.06 g, I2 = 38%, p< 0.001) (Fig 3B). In three studies [38,39,55] including
421 participants, metformin-exposed neonates were lighter by an average of 191.37 g (95% CI
−288.01 g to −94.74 g, I2 = 0%, p< 0.001) compared to those exposed to glyburide (Fig 3C).
In seven studies including 1,587 participants [32,35,36,50,53,58,59], neonates exposed to
glyburide had increased rates of macrosomia compared to insulin-exposed neonates (OR 1.38,
95% CI 1.01 to 1.89; I2 = 31%, p = 0.04) (Fig 4A). In 10 studies including 1,810 women
Fig 2. Total gestational weight gain for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide
comparisons. Expressed as mean difference and fixed effects model, except metformin versus insulin (expressed as random effects model). All
comparisons 95% CI. CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1003126.g002
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[31,33,34,40,41,42,44,45,54,56], metformin-exposed neonates had reduced rates of macroso-
mia compared to insulin-exposed neonates (OR 0.60, 95% CI 0.45 to 0.79, I2 = 5%, p< 0.001)
(Fig 4B). In two studies including 221 women [38,55], there was a nonsignificant decrease in
macrosomia in metformin-exposed compared to glyburide-exposed neonates, although this
did not reach statistical significance (OR 0.32, 95% CI 0.08 to 1.19, I2 = 0%, p = 0.09) (Fig 4C).
In meta-analyses comparing LGA rates between groups, although the trends were similar to
meta-analyses for macrosomia, there were fewer studies available for analysis. In four studies
including 587 women [35,36,53,58], LGA rates did not show a statistically significant differ-
ence between glyburide-exposed versus insulin-exposed neonates (OR 2.49, 95% CI 0.79 to
7.81, I2 = 65%, p = 0.12) (Fig 5A). In five studies including 1,343 women [33,34,40,43,45], LGA
incidence was unchanged between metformin- and insulin-exposed neonates (OR 0.87, 95%
CI 0.66 to 1.14, I2 = 26%, p = 0.31) (Fig 5B). In two studies of 272 women [38,39], LGA was sig-
nificantly decreased in metformin-exposed neonates compared to those exposed to glyburide
in utero (OR 0.38, 95% CI 0.18 to 0.78, I2 = 0%, p = 0.008) (Fig 5C).
Fig 3. Birth weight for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as
mean difference (fixed effects model) and 95% CI. CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1003126.g003
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Neonatal ponderal index was reported in two studies [50,53], including 974 women in gly-
buride versus insulin comparisons. Glyburide-exposed neonates had a similar ponderal index
compared to insulin-exposed neonates (−0.01, 95% CI −0.49 to 0.46, I2 = 0%, p = 0.96). In met-
formin versus insulin comparisons, three studies of 986 women [41,43,47] demonstrated that
neonates exposed to metformin had a reduced ponderal index compared to insulin-exposed
neonates (−0.13, 95% CI −0.26 to −0.00, I2 = 0%, p = 0.04). Only one study [39] including 200
women reported ponderal index comparing glyburide with metformin. Neonates exposed to
Fig 4. Macrosomia for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as
mean difference (random effects model). Expressed as OR (fixed effects model) and 95% CI. CI, confidence interval; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003126.g004
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metformin during gestation had decreased ponderal index (−0.09, 95% CI −0.17 to −0.01, I2 =
non-applicable [N/A], p = 0.03) compared to neonates exposed to glyburide (Table 3).
Only one study of 82 women [53] reported neonatal anthropometric outcomes (neonatal
head, chest, and abdominal circumferences) in glyburide versus insulin comparisons. Neo-
nates exposed to glyburide during gestation had similar head circumferences (0.30 cm, 95% CI
−0.31 to 0.91, I2 = N/A, p = 0.30) and increased chest (0.80 cm, 95% CI 0.07–1.53, I2 = N/A,
p = 0.02) and abdominal circumferences (0.90 cm, 95% CI 0.03–1.77, I2 = N/A, p = 0.04) com-
pared to insulin-exposed babies. Neonatal anthropometry was reported in up to three studies
including 986 women that compared metformin to insulin [33,41,43]. Metformin-exposed
babies had smaller head (−0.21 cm, 95% CI −0.39 to −0.03, I2 = 53%, p = 0.02) and chest cir-
cumferences (−0.34 cm, 95% CI −0.62 to −0.05, I2 = 42%, p = 0.02), yet no difference in
abdominal circumference (0.00 cm, 95% CI −0.44 cm to 0.44 cm, I2 = N/A, p = 1.00), com-
pared to those exposed to insulin (Table 3). In metformin versus glyburide studies, no neonatal
anthropometry was reported.
Fig 5. LGA for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as OR
(fixed effects model) with the exception of the glyburide versus insulin comparison (random effect model). All comparisons 95% CI. CI, confidence
interval; LGA, large for gestational age; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003126.g005
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Only one study [53] of 71 women compared glyburide with insulin and reported measures
of neonatal adiposity. This demonstrated a nonsignificant increase in total fat mass in glybur-
ide- versus insulin-exposed neonates (102.3 g, 95% CI −3.91 g to 210.91 g, I2 = N/A, p = 0.06).
Tricep skinfold (0.10 cm, 95% CI, −0.11 cm to 0.31 cm, I2 = N/A, p = 0.34) or subscapular skin-
fold thicknesses were unchanged (0.00 cm, 95% CI −0.35 cm to 0.35 cm, I2 = N/A, p = 1.00)
between glyburide- and insulin-exposed groups. In metformin versus insulin comparisons,
one study of 733 women [43] reported neonatal adiposity indices. This study demonstrated no
difference in neonatal tricep skinfold (0.10 cm, 95% CI −0.11 cm to 0.31 cm, I2 = N/A,
p = 0.34) or subscapular skinfold thicknesses (0.00 cm, 95% CI −0.20 cm to 0.20 cm, I2 = N/A,
p = 1.00); however, neonatal total fat mass was not reported. No fat anthropometric data were
reported for the metformin versus glyburide comparison (Table 3).
With respect to neonatal outcomes, several analyses failed LOO sensitivity analysis (birth
weight comparing glyburide with insulin, LGA comparing metformin with glyburide, and
macrosomia comparing metformin with insulin), and these analyses should therefore be inter-
preted with caution.
Later postnatal outcomes
No eligible studies comparing glyburide with insulin or with metformin looked at any postna-
tal growth outcomes later than the neonatal period. Previously, we reported that studies com-
paring metformin with insulin have shown increased infant weight, increased childhood BMI,
and evidence of increased adiposity [29].
Discussion
Our results demonstrate that babies exposed to glyburide are significantly heavier at birth and
have increased incidence of macrosomia compared to those whose mothers were randomised
to insulin. Conversely, metformin-exposed babies are significantly lighter at birth and have
reduced incidence of macrosomia compared to insulin-exposed babies. Babies whose mothers
were randomised to metformin versus glyburide were significantly lighter and significantly
less likely to be born LGA. In addition to birth weight differences, our findings also suggest
that there may be differences in neonatal body composition between treatment groups. In par-
ticular, glyburide-exposed babies have increased abdominal circumference and a nonsignifi-
cant increase in total fat mass compared to the insulin-exposed group, and higher ponderal
Table 3. Neonatal anthropomorphic characteristics.
Anthropomorphic characteristics Glyburide versus insulin Metformin versus insulin Metformin versus glyburide
Ponderal index −0.01 [−0.49 to 0.46] −0.13 [−0.26 to −0.00] # −0.09 [−0.17 to −0.01] #
Head circumference 0.30 [−0.31 to 0.91] −0.21 [−0.39 to −0.03] # No studies
Chest circumference 0.80 [0.07 to 1.53] " −0.34 [−0.62 to −0.05] # No studies
Abdominal circumference 0.90 [0.03 to 1.77] " 0.00 [−0.44 to 0.44] No studies
Total fat mass 102.3 [−3.91 to 210.91]† No studies No studies
Triceps skinfold thickness 0.00 [−0.35 to 0.35] 0.10 [−0.11 to 0.31] No studies
Subscapular skinfold thickness 0.40 [−0.10 to 0.90] 0.00 [−0.20 to 0.20] No studies
All outcomes expressed as mean difference. All outcomes used fixed model effects and 95% CI. Units: head circumference, cm; chest circumference, cm; abdominal
circumference, cm; ponderal index, kg/m3.
†Increase not meeting statistical significance (p = 0.06).
" Increased (p < 0.05).
# decreased (p < 0.05).
https://doi.org/10.1371/journal.pmed.1003126.t003
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index compared to the metformin-exposed group. Conversely, babies born to mothers treated
with metformin have a reduced ponderal index compared to either insulin- or glyburide-
exposed babies. Although limited suitable studies are available for inclusion in these meta-
analyses, a clear picture emerges of babies exposed to glyburide being born larger and with
increased adipose mass, and babies exposed to metformin being born smaller and with
reduced lean mass, compared to those treated with standard insulin therapy.
Despite the significant differences in neonatal anthropometry at birth, we found that met-
formin, glyburide, and insulin were all equally effective for maternal glycaemic control (when
supplementary insulin was available as required), as evidenced by FBS, RBS, or HbA1c mea-
surement. Although there are there are limitations associated with the use of HbA1c as an
index of glycaemic control in GDM (as it reflects glycaemic control over several months), the
observation that all three different assessments led to the same conclusion gives confidence in
this finding. Moreover, no study utilised HbA1c to assess glycaemic control alone. With regard
to the relative merits of treating GDM with metformin versus glyburide from a maternal point
of view, we demonstrate that metformin has a higher likelihood of treatment failure and
requiring supplementary insulin than glyburide, but it is also associated with less gestational
weight gain than either glyburide or insulin.
Strengths
Our study design incorporates all key comparisons required to fully evaluate the impact of
pharmacological treatment of GDM on neonatal anthropometry and maternal glycaemic con-
trol. The ability to perform the numerous relevant comparisons within a single comprehensive
study design is a major strength of this work. Having fully recognised the paucity of studies
reporting key data for some outcomes, we have performed extensive evaluation of the robust-
ness of our conclusions, and urge a conservative view to interpretation. However, even allowing
for this highly cautious approach, a clear pattern of nonequivalence amongst therapies emerges
with respect to neonatal size and body composition. Where possible, we have performed multi-
ple sensitivity analyses to take account of other variables, for example, the differing criteria used
to diagnose GDM and the various global contexts within which the studies were performed.
Limitations
The ability to draw definitive conclusions from our meta-analysis is limited by both the quantity
and quality of the studies available. With respect to glyburide, in particular, few studies met the
inclusion criteria (8 studies comparing glyburide to insulin, versus 22 studies comparing met-
formin to insulin). Moreover, our comparisons of metformin versus glyburide treatment are
based on relatively sparse data relating to only 421 women (3 studies). Our findings highlight
the surprising lack of high-quality data on which to base clinical recommendations regarding
oral anti-hyperglycaemic agents in the treatment of GDM. The lack of high-quality data results
in the need for caution in interpretation of the analyses that are not robust to sensitivity testing.
None of the eligible studies reported the effects of pharmacological intervention for GDM
on fetal growth outcomes. Clearly, weight and body composition at birth are products of fetal
growth in utero, and without fetal data, it is challenging to deduce what underlying mecha-
nisms may be driving the observed neonatal outcomes. In light of our findings, there is an
urgent need to report fetal growth data in future studies. Similarly, we were unable to compare
postnatal growth patterns between treatment groups. No eligible studies comparing glyburide
to either insulin or metformin have reported any growth outcomes beyond the immediate
neonatal phase. We have previously reported that children exposed to metformin versus insu-
lin in utero are smaller at birth but have accelerated postnatal growth [29]. Our findings of
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altered birth weight and fat mass in babies exposed to oral anti-hyperglycaemic drugs in utero
highlight a future research need for longitudinal studies of growth and body composition fol-
lowing intrauterine glyburide or metformin exposure.
Interpretation and implications
When GDM is managed using diet and lifestyle interventions, or with insulin, maternal glycae-
mic control can be used as a proxy for fetal growth outcomes [3]. Although insulin does not
cross the placental barrier [60,61], metformin and glyburide both do. Our results imply that
other direct and indirect mechanisms impact on regulation of fetal growth when oral anti-
hyperglycaemic agents are used in GDM treatment.
Glyburide has been detected in umbilical cord blood concentrations up to 70% of those
observed in the maternal circulation [25–27]. Glyburide is thought to be transported across
the placenta via ATP-binding cassette protein (ABC) transporters located in both the apical
and basolateral membranes of the syncytiotrophoblast. The relationship between maternal and
fetal glyburide levels is complicated by the drug’s high protein binding and active feto-mater-
nal efflux [25,62]. The normalisation of maternal euglycaemia by glyburide relies on stimulat-
ing increased insulin production from maternal beta cells. However, as glyburide also reaches
the fetal beta cells across the placental barrier, these may also be directly stimulated to excess
insulin production. Fetal plasma insulin is a critical regulator of fetal growth, linking both
nutrient supply and anabolic signals for growth [63]. There is therefore a plausible mechanism
by which direct fetal exposure to glyburide and stimulation of fetal insulin secretion could
result in fetal overgrowth and adiposity, even in the absence of maternal hyperglycaemia.
Fetal circulating metformin levels can approach or exceed those in the maternal circulation
[22–24]. Organic cation transporters, key to transporting metformin intracellularly, are pres-
ent in both placental and fetal tissues by the time GDM treatment is initiated in the second
and third trimester [64,65]. One of metformin’s major intracellular effects is on the mamma-
lian target of rapamycin (mTOR) pathway, known to be important for nutrient sensing, by
both 50 AMP-activated protein kinase (AMPK)-dependent [66] and AMPK-independent [67]
mechanisms. It is possible that metformin-induced mTOR inhibition could restrict placental
nutrient transfer, hence limiting transport of glucose and amino acids [68] and potentially pro-
viding a mechanism for lower birth weight and reduced ponderal index observed in metfor-
min-exposed neonates compared to their insulin- or glyburide-exposed counterparts.
Metformin reduces cellular energy production via inhibition of complex I of the mitochondrial
electron transport chain, leading to an increase in both ADP/ATP and AMP/ATP ratios,
inhibiting (mTOR) actions and down-regulating pathways associated with cell growth and
proliferation [69,70]. There is therefore an urgent research need to investigate these potential
mechanisms by which oral anti-hyperglycaemic agents could impact on fetal growth (Fig 6),
particularly in view of their increasing clinical use.
Our results suggest that there may not be a single optimal pharmacological agent for treat-
ment of GDM across all global contexts. Birth weight was increased by glyburide (versus insu-
lin) to a greater extent in studies performed in the US/Latin America than in other global
contexts, whereas studies from North Africa/Middle East showed a greater decrease in birth
weight with metformin (versus insulin) than studies performed elsewhere. This potentially
reflects different underlying mechanisms of gestational diabetes in different populations, for
example, peripheral insulin resistance versus beta cell dysfunction, potentially due to differing
genetic backgrounds or different environmental challenges. There may also be population dif-
ferences in patient preference for treatment options (for example, insulin may be preferred to
adding a second oral agent [71]), which are important to consider given that outcomes rely on
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Fig 6. Summary diagram of the mechanisms of action of GDM intervention on mother and baby. GDM, gestational diabetes
mellitus.
https://doi.org/10.1371/journal.pmed.1003126.g006
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treatment concordance. In addition to the logistic challenges of delivering a context-appropri-
ate agent (for example, avoiding insulin where refrigeration is not practicable), our results sug-
gest that the efficacy of anti-hyperglycaemic agents in promoting normal fetal growth may
vary across contexts. This is an important target for future research to inform health policy
and reflects heterogeneity in the condition of GDM.
Our findings show significant differences in neonatal body weight and anthropometric param-
eters between babies whose mothers were randomised to glyburide, metformin, and insulin to
treat GDM, even with equivalent maternal glycaemic control. Our results highlight the impor-
tance of considering the effects of treatment on both mother (glycaemic control) and baby (fetal
growth) when managing GDM. The lack of data for inclusion in these meta-analyses is concern-
ing, given that numerous bodies worldwide already endorse the use of oral anti-hyperglycaemic
agents as first- or second-line treatments for GDM [14,15,17,18]. Examining in detail the mecha-
nisms by which the various pharmacological options for GDM treatment may impact the devel-
oping fetus and/or placenta in both the short and long term is particularly important, given the
increasing incidence of GDM worldwide [1,2]. Most significantly, the greatest increases in GDM
globally are occurring in populations in which treating GDM with insulin is unlikely to be feasible
for large numbers of women [72]. Further understanding of how oral anti-hyperglycaemic agents
impact on fetal growth trajectory and later life outcomes should therefore be a research priority.
There is an urgent need for further data to define the potential risk associated with GDM treat-
ments and lifetime risk of adverse metabolic outcomes for the infant.
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